Chapter 96

Nature is one of the most authoritative academic journals in the world, and is also regarded by many scientific and technological workers as one of the highest halls of academic papers.

Many influential industries and scientific research achievements are usually favored by nature.

Meade's logic is very simple. He heard that the paper on symbiotic protein of origin technology had been submitted to nature, but there was no paper on birds in nature, let alone published.

If symbiotic photosynthetic green leaf protein is really realized and can really change the course of biomedicine, there is no reason why nature should not be published.

After interviewing Meade and others, the New York Times reported the absurd scam of symbiotic photosynthetic green leaf protein under the title of "technology is not science fiction".

The New York Times has two bases for this report.

One was a field interview with Huaxi Hospital. It was found that many patients with lung diseases were still waiting there and did not receive the so-called symbiotic bacteria treatment.

The New York Times certainly cannot interview patients who have been treated, because these patients are still under observation and will not be interviewed by reporters at all. In addition, the production of symbiotic bacteria is not much, and it can not meet the needs of a large number of patients for treatment.

The second is that the international mainstream academic circles scoff at the technology of symbiotic photosynthetic green leaf protein, and even don't bother to comment. In Xia state, only one third rate academic journal published this paper, which is enough to illustrate the unreliability of this technology.

Like the western media such as the New York Times, which have long reported the prejudice against Xia, this article costs most of the Western gossip alone.

However, the report of the Chinese version of the New York Times is different. The title has become "a large number of patients waiting for treatment with new technology", and the content is also very neutral, just like describing Zhang San's going to Li Si's family for dinner.

Look, the media also want the right meal.

In addition to the New York Times, many technology columnists are also writing articles to attack the illusion of symbiotic proteins.

After all, everyone needs a proper meal. Symbiotic protein is a rare topic at present. Who do you write?

Zhou Xiao has no time to chat or read the report of the New York Times.

[technology product: symbiotic photosynthetic green leaf protein. Monopoly value, urban 17.3%; Aversion value, city 3.2%.]

Symbiotic proteins have formed a wide influence in the domestic medical community. Before expanding the scale of treatment, the monopoly value will not increase much.

At present, the monopoly value is much higher than the aversion value. Zhou Xiao's choice is also very simple and continues to expand the influence of this technology.

It can not only cure diseases and save people, but also increase monopoly value and make money, which is also a win-win choice.

The final cost of symbiotic protein treatment was also calculated.

Chen Hao drove from the factory to the headquarters with a stack of materials and reported the situation to Zhou Xiao.

Chen Hao has become the team leader of the life science laboratory and realized his life value.

He now recalls what Zhou Xiao said when he just joined Genesis Technology. As expected, none of the words were farting, and all of them were realized.

Chen Hao handed the information to Zhou Xiao and said, "President Zhou, if you don't calculate the early investment, only calculate the cost of symbiotic bacteria production, preservation and transportation, about 400 yuan per cubic centimeter."

Chen Hao added: "because our production line is limited now, all strains can not get effective profits. In the future, after the plant in the new science and technology zone is completed, the cost will be greatly reduced."

Zhou Xiao estimated the cost, 400 yuan per cubic centimeter. According to the calculation of 200 to 300 square centimeters transplanted by ordinary people, the cost of one treatment is 80000 to 120000, which is the cost price of origin technology.

Zhou Xiao should calculate not only the cost, but also the profit.

Origin technology must not make money against conscience for domestic patients, but it must be 20% higher than the cost before large-scale mass production to maintain the normal operation of the company and subsequent production increase, production expansion and scientific research.

Besides, there is a huge initial investment in origin technology, which should be recovered slowly.

In this way, the price is 480 yuan per cubic centimeter, and the total cost is about 96000 to 144000.

If patients are treated in the hospital, the cost will rise, and the cost should be about 200000.

200000, all at the patient's own expense.

For patients with a better family, 200000 can fully bear it, which is not a problem at all.

But how many of those patients with pneumoconiosis and interstitial pneumonia have good family conditions?

According to official statistics, there are about 6 million pneumoconiosis patients in Xia country.

Most of these 6 million are bottom workers, engaged in industries with high dust and high pollution, with a meager salary. They have to support their families with this money. It is difficult to get 20000. Where is 200000 for treatment.

Zhou Xiao frowned and paced back and forth in the office.

If patients can't afford it, the treatment technology of symbiotic protein can't be covered and popularized.

This is not a question of whether to make money, but a question of whether the monopoly value can not meet the requirements and can not complete the task.

If the panel has been stuck in symbiotic protein, Zhou Xiaofei will be wrong! Chang! no Go! Heart!

How to make this technology not only widely popularize patients, but also make origin technology not lose money is a problem.

The way Zhou Xiao can think of is crowdfunding!

Mobilize social resources to help patients, which can not only reduce the burden of patients, but also popularize treatment technology.

Crowdfunding needs to cooperate with some disease crowdfunding treatment companies and even insurance companies to let the other party bring symbiosis treatment into the scope of crowdfunding treatment, but it depends on whether the other party has relevant intention.

When Yuanyuan technology contacted some crowdfunding platform companies, President Peng of Jiangcheng people's court found Zhou Xiao.

Because of the establishment of oasis hair transplant center, the income and influence of Jiangcheng people's hospital have increased a lot.

But as a general hospital, how can president Peng be willing to turn Jiangcheng people's Hospital into a simple hair transplant center?

Jiangcheng people's hospital has long cooperated with origin technology. Now he is not happy to see that origin technology puts the revolutionary treatment technology such as symbiotic protein in Huaxi Hospital in Chengdu instead of Jiangcheng hospital.

This personal visit is to build a more professional respiratory medicine.

The reason given by President Peng is also very persuasive. "In the old industrial city of Jiangcheng, in terms of the number of pneumoconiosis patients, the number in Jiangcheng row, let the patients treat at home, and the headquarters work hard to go to Chengdu, okay?"

Zhou Xiao is ashamed. There are many pneumoconiosis patients. Is this worth bragging about?

Zhou Xiao originally planned to expand the influence scope of symbiotic protein treatment. Of course, he was willing to cooperate with Jiangcheng people's Hospital and put forward his own cooperation plan.

Jiangcheng people's Hospital and origin technology jointly established a respiratory medicine treatment center.

The center is under the jurisdiction of the hospital. Origin technology provides products and sends technical guidance personnel to guide doctors for treatment.

Zhou Xiao sent technicians mainly to try adjuvant treatment for lung cancer patients in addition to guidance, which is still a gap in current clinical trials.

But when Zhou Xiao took out the treatment cost of symbiotic protein, director Peng was really embarrassed.

"In this way, it will cost 200000 yuan for treatment. Symbiotic protein has just been in clinical treatment and has not been included in medical insurance. Patients pay more than 200000... I'm afraid many people can't afford it."

Just then, Wang Yulan returned the news.

Several large crowdfunding platforms have said that pneumoconiosis, interstitial pneumonia and lung cancer are the scope of crowdfunding, and they don't care how the hospital treats them.

But the problem comes again. Crowdfunding needs time and various harsh terms (forwarding times, exposure time, etc.).

For patients who race against life, I'm afraid they haven't raised enough money and there are no people.

Besides, those workers who live at the bottom may not use smartphones, let alone know what crowdfunding is.

Peng Yufei also felt that it would be unreliable to place all his hopes on crowdfunding.

They tried to find a way.